Loading organizations...
§ Private Profile · 3805 Old Easton Road Doylestown, PA 18902 United States
Novira Therapeutics is a company.
Novira Therapeutics has raised $34.5M across 3 funding rounds.
Key people at Novira Therapeutics.
Novira Therapeutics has raised $34.5M in total across 3 funding rounds.
Novira Therapeutics develops first-in-class antiviral therapies for chronic hepatitis B (CHB) infection. Its technical approach identifies compounds targeting viral capsid assembly, a novel mechanism designed to disrupt the HBV replication cycle. This strategy provides effective solutions for a global disease with significant unmet medical need.
Founded in 2009 by Dr. Ali H. Munawar, a Harvard-trained scientist, alongside George Hartman and Osvaldo Flores, Novira Therapeutics emerged from intellectual property demonstrating a new antiviral intervention pathway. The team recognized the potential of targeting HBV's capsid assembly to create superior treatments, establishing the company's specialized research focus.
Novira Therapeutics addresses the pressing need for improved treatment options for individuals with chronic hepatitis B worldwide. The company’s vision is to deliver curative or highly effective therapies that transform CHB management, achieving functional cures for patients and significantly improving outcomes.
Key people at Novira Therapeutics.
Novira Therapeutics has raised $34.5M across 3 funding rounds. Most recently, it raised $9.0M Debt in December 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 24, 2014 | $9M Debt Financing | — | — | Announced |
| Mar 1, 2013 | $25M Series A | — | 5AM Ventures, Canaan Partners, Venrock, TIM Shannon, Gianni Gromo | Announced |
| Jul 26, 2011 | $500K Seed | Delaware Crossing Investor Group, Karen Griffith Gryga, Gregory Harriman | Barbara S. Schilberg | Announced |
Novira Therapeutics has raised $34.5M in total across 3 funding rounds.
Novira Therapeutics's investors include 5AM Ventures, Canaan Partners, Venrock, Tim Shannon, Gianni Gromo, Delaware Crossing Investor Group, Karen Griffith Gryga, Gregory Harriman, Barbara S. Schilberg.
Novira Therapeutics was a clinical-stage biopharmaceutical company developing first-in-class oral antiviral therapies targeting the viral capsid for chronic hepatitis B (CHB) and HIV infections, addressing major global unmet needs in infectious diseases.[1][2] It served patients with these chronic viral infections, aiming to provide novel monotherapies or combinations superior to existing standards of care, with a focus on HBV as a primary indication.[1][2]
The company demonstrated early promise in drug discovery but was ultimately acquired by Johnson & Johnson in 2016, integrating its pipeline into Janssen's Infectious Diseases & Vaccines unit, which accelerated development amid J&J's push for innovative therapies like Darzalex.[3][4]
Novira Therapeutics emerged from Versant Ventures' portfolio, backed by investors including Johnson & Johnson Innovation, with a founding focus on novel antivirals for HBV and HIV.[1][2] Key leadership included experienced executives like Schade, previously at Medarex (acquired by Bristol-Myers Squibb), bringing expertise in antibody therapeutics, oncology, and infectious diseases from roles at Merrill Lynch and JP Morgan.[2]
The idea stemmed from targeting the viral capsid—a underexplored mechanism for oral drugs—gaining traction through preclinical advancements that positioned it for acquisition by J&J's Janssen in 2016, amid J&J's strategy of bolt-on deals to bolster its pipeline against patent cliffs on blockbusters like Remicade.[3][4]
Novira rode the wave of structure-based drug design in antivirals, capitalizing on HBV's 250+ million chronic carriers worldwide and the push beyond suppressive therapies toward functional cures.[1][2] Timing aligned with 2010s biotech M&A surge, as big pharma like J&J addressed pipeline gaps from patent expirations (e.g., Remicade biosimilars) via acquisitions like Novira, alongside Alios BioPharma and others.[3][4]
It influenced the ecosystem by validating capsid inhibitors as a viable class—now pursued by peers—while amplifying J&J's infectious disease portfolio, contributing to goals like 10 novel blockbuster therapies by decade's end.[3]
Post-acquisition, Novira's assets advanced within Janssen, potentially yielding HBV candidates amid rising demand for curative antivirals amid evolving standards like siRNA combos. Trends like AI-driven protein modeling and combo regimens will shape progress, with J&J's scale positioning remnants for Phase II/III milestones or partnerships.[3][4]
Its legacy underscores nimble biotech's role in feeding pharma pipelines, evolving from standalone innovator to integrated powerhouse in the fight against viral pandemics.
